Detailed Information on Publication Record
2003
Second-line treatment with gefitinib (Iressa, ZD 1839) in patient with advanced non-small-cell lung cancer.
SKRICKOVA, Jana, Lenka BABICKOVA, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PÁLKOVÁ et. al.Basic information
Original name
Second-line treatment with gefitinib (Iressa, ZD 1839) in patient with advanced non-small-cell lung cancer.
Name (in English)
Second-line treatment with gefitinib (Iressa, ZD 1839) in patient with advanced non-small-cell lung cancer.
Authors
SKRICKOVA, Jana (203 Czech Republic, guarantor), Lenka BABICKOVA (203 Czech Republic), Jana KAPLANOVÁ (203 Czech Republic), Olga KUBOVÁ (203 Czech Republic), Ivana PÁLKOVÁ (203 Czech Republic) and Marcela TOMÍSKOVÁ (203 Czech Republic)
Edition
Madrid, Spain, Woorkbook of Iressa Clinical Experience Meeting, p. 81-81, 2003
Publisher
AstraZeneca
Other information
Language
Czech
Type of outcome
Stať ve sborníku
Field of Study
30203 Respiratory systems
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/03:00008834
Organization unit
Faculty of Medicine
Keywords in English
non-small-cell lung cancer; gefitinib treatment; antitumour activity;
Změněno: 31/7/2003 11:07, prof. MUDr. Jana Skřičková, CSc.
V originále
A case is presented of a 73-year old female non-smoker with advanced, symptomatic NSCLC, initially treated with gemcitabine and carboplatin, but improved only after oral gefitinib 250mg/day, which was well tolerated and demonstrated good antitumour activity.
In English
A case is presented of a 73-year old female non-smoker with advanced, symptomatic NSCLC, initially treated with gemcitabine and carboplatin, but improved only after oral gefitinib 250mg/day, which was well tolerated and demonstrated good antitumour activity.
Links
| MSM 141100003, plan (intention) |
|